SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is drawing attention after reaching a 52-week high ahead of an expected Q3 report, with traders watching BRIUMVI sales and whether results support the rally. Buyout speculation and possible short covering are also prominent, but the acquisition talk is unconfirmed and some traders attribute the strength to the companys operating momentum instead.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons quarterly results and heavy AI infrastructure spending drove debate, as investors weighed weaker-than-expected results and sharply negative free cash flow against accelerating AWS growth and its outlook. Traders were split between concerns that cash burn and rising investment could pressure the stock and dip-buyers who viewed the initial selloff as overdone; shares rebounded substantially from their lows.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Better-than-expected quarterly results and strength in parks and streaming have renewed optimism, with traders pointing to analyst upgrades and a potential technical breakout. Others remain skeptical, citing Disneys long-running share-price stagnation and resistance levels.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels steep drop followed weak forward guidance despite a solid quarter, with traders focused on softer PC demand, manufacturing constraints and analyst downgrades; the pressure also fed into a broader semiconductor and tech selloff. The community is split between calling the reaction excessive and buying the dip, and warning that the outlook and execution problems could prolong the decline.

United States Natural Gas Fund LP. - United States Natural Gas Fund

United States Natural Gas Fund, LP

UNG is drawing attention as natural gas prices slide amid mild-weather forecasts that point to weaker heating demand, with surplus inventories adding pressure. Traders are split between buying the decline ahead of winter and expecting further weakness if warm conditions persist; colder forecasts or storage data are seen as potential catalysts for a shift.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit is drawing attention ahead of the November 14 FDA decision on ivonescimab plus chemotherapy for EGFR-mutated lung cancer, with traders weighing the Phase 3 results and recent positive biliary-cancer data against regulatory concerns, including the lack of statistically significant overall-survival results. Bulls see approval potential and broader promise for the drug, while skeptics stress that the decision remains uncertain and could hinge on FDA concerns about the trial population or manufacturing.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the upcoming FDA decision on Capricors deramiocel for Duchenne muscular dystrophy, with traders focusing on the amended upper-limb-function data and recent rare-disease discussions. New commercial-launch job postings and other FDA approvals have fueled optimism about a favorable decision, while skeptics caution that neither hiring nor regulatory flexibility guarantees approval and debate the risk of a CRL; some also attribute price swings to short covering or rumors of a leak.

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Agenuss BOT+BAL combination drew attention after Phase 2 NEOASIS data at ESMO showed strong pathologic responses in a small dMMR colon cancer cohort, alongside discussion of sarcoma results. Traders called the findings encouraging but debated their significance given the small, early-stage studies and awaited Phase 3 confirmation, while some questioned why the share price weakened despite the data and raised dilution and execution concerns.

Hedera (HBAR) is a cryptocurrency launched in 2017. Hedera has a current supply of 50,000,000,000 with 44,327,155,828.93500734 in circulation. The last known price of Hedera is 0.07221819 USD and is up 4.74 over the last 24 hours. It is currently trading on 465 active market(s) with $92,347,671.42 traded over the last 24 hours. More information can be found at https://www.hedera.com/.

Hedera Hashgraph

HBARs sharp rally and elevated volume are being linked by traders to IBM-related cloud news and Hederas reported connections to NVIDIAs AI safety platform. Enthusiasm over enterprise and AI use cases is tempered by profit-taking and skepticism that the announcements will translate into meaningful adoption or token demand.

Cameco Corp. engages in the provision of uranium. It operates through the following segments: Uranium and Fuel Services. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Camecos Q3 report and narrower 2026 production guidance are driving the selloff, with traders focusing on weaker results and production setbacks, including at Cigar Lake. Some see the report as disappointing and the stock as overvalued, while long-term bulls point to firm uranium prices and nuclear demand.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Solventum (SOLV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Solventum (SOLV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why Solventum (SOLV) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

SOLV Wins FDA Clearance to Combine Restrata Matrix With V.A.C.Therapy

Solventum gains FDA clearance to combine Restrata Matrix with V.A.C. Therapy, potentially expanding wound care applications and supporting long-term growth.

Elevance Health (ELV) Surpasses Q3 Earnings and Revenue Estimates

Elevance Health (ELV) delivered earnings and revenue surprises of +50.00% and +4.01%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Solventum Announces FDA 510(k) Clearance for Combined Use of Restrata Matrix and Solventum V.A.C. Therapy*

Solventum Announces FDA 510(k) Clearance for Combined Use of Restrata Matrix and Solventum V.A.C. Therapy* Solventum Announces FDA 510(k) Clearance for Combined Use of Restrata Matrix and Solventum V.A.C. Therapy*PR NewswireEAGAN, Minn., Oct. 19, 2026 First-of-its-kind clearance combines two...

Solventum to Report Third Quarter Fiscal 2026 Earnings on November 5, 2026

Solventum to Report Third Quarter Fiscal 2026 Earnings on November 5, 2026 Solventum to Report Third Quarter Fiscal 2026 Earnings on November 5, 2026PR NewswireEAGAN, Minn., Oct. 15, 2026EAGAN, Minn., Oct. 15, 2026 /PRNewswire/ -- Solventum(NYSE: SOLV) will release its third quarter fiscal 2026...

Can Solventum (SOLV) Keep the Earnings Surprise Streak Alive?

Solventum (SOLV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Solventum (SOLV) is a Top Value Stock for the Long-Term

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Solventum Corp. operates as a health care company. It gives better, smarter, safer healthcare to improve lives. The company was founded on January 24, 2023 and is headquartered in Maplewood, MN.

Solventum Corp

Retail Investors Hail 3M’s Earnings Amid Historic Stock Surge: ‘New CEO Gonna Turn This Thing Around’

Equity

Bullish Sentiment

Shares of Post-It notes maker 3M (MMM) surged by as much as 18% to $122.68 on Friday, marking their most significant intra-day gain since 1987, according to <a href="https://www.bloomberg.com/news/articles/2024-07-26/3m-raises-profit-forecast-as-new-ceo-brown-takes-helm">Bloomberg</a>, and lifted retail sentiment to the highest in a year.&nbsp;Stocktwits sentiment for MMM reached an extremely bullish level (95/100) on Friday morning amid exceptionally high message volumes (97/100) — with both metrics hitting their highest in 12 months — pushing the stock to fourth among the top 10 trending symbols on the platform.<figure class="image"><a href="https://stocktwits.com/symbol/MMM"><img style="aspect-ratio:1320/312;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/MMM_sentiment_and_message_volume_score_on_Jul_26_c81096dd8d.png" alt="MMM sentiment and message volume score on Jul 26.png" width="1320" height="312"></a><figcaption>MMM sentiment and message volume score on Jul 26</figcaption></figure>“The breakout we have been waiting for. This could be at $140 in the blink of an eye. One of the best performing under the radar industrials. New CEO gonna turn this thing around,” read a bullish <a href="https://stocktwits.com/lion3539/message/580796011">post</a> from Stocktwits user Jack Pezzeli.<figure class="image"><a href="https://stocktwits.com/lion3539/message/580796011"><img style="aspect-ratio:1320/398;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Stocktwits_user_Jack_Pezzeli_s_post_on_MMM_stream_Jul_26_1a2ee2d642.png" alt="Stocktwits user Jack Pezzeli's post on MMM stream Jul 26.png" width="1320" height="398"></a><figcaption>Stocktwits user Jack Pezzeli's post on MMM stream Jul 26</figcaption></figure>The industrial conglomerate's impressive performance was driven by a combination of better-than-expected second-quarter earnings and a renewed investor confidence in the company's strategic direction under the leadership of new CEO Bill Brown.3M reported earnings per share of $1.93, surpassing analyst estimates of $1.68. The company also raised its full-year profit forecast, signaling management confidence that the momentum can continue.&nbsp;These positive results come on the heels of a tumultuous period for the company, marked by significant restructuring, including the spin-off of its healthcare division, workforce reductions, and facility closures.Brown's strategic pivot towards higher-growth areas, such as automotive electrification and climate technology, has resonated well with investors. The company's decision to exit less profitable consumer product lines has also been met with approval.Wall Street analysts have already echoed the positive sentiment. Barclays recently increased its price target for 3M, while Wolfe Research last month upgraded the stock to "Outperform" and set a year-end 2024 price target of $125, impressed by Brown's track record at defense contractor L3Harris (LHX).3M said in a video to employees in May that innovation-driven organic growth and operating efficiency would be Brown’s two top priorities.As the company embarks on a new chapter under Brown's leadership, its ability to sustain its momentum and capitalize on emerging opportunities will be closely watched by investors. The stock is up over 37% year-to-date.Photo courtesy: 3M

Shares of Post-It notes maker 3M (MMM) surged by as much as 18% to $122.68 on Friday, marking their most significant intra-day gain since 1987, according to Bloomberg, and lifted retail sentiment to the highest in a year.

3M stock surges as retail investors praise earnings

The industrial giant's Q2 earnings and optimistic outlook, coupled with enthusiasm for CEO Bill Brown's leadership, is making retail investors swoon over the stock.


Pacer Funds Trust - Pacer US Cash Cows 100 ETF

3M Co.

Industrial Select Sector SPDR Fund

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

SOLV News